Eurofins: Sustained Growth Momentum Bodes Well for the Full Year 2013
November 04 2013 - 12:30AM
Business Wire
- Revenues increased over 17%
year-on-year to EUR 882m.
- Organic growth of over 6% as momentum
remains strong across most markets. Excluding businesses that are
in significant restructuring, organic growth stood at 7.5%.
- Strong performance across most areas of
our business.
Regulatory News:
Comments from the CEO, Dr. Gilles Martin: “The results
achieved year to date reflect the strength that we have built into
our network. We have the ability to invest in projects that may be
dilutive in the near-term, but create significant long-term value.
The impact of these investments is offset by the strong performance
in the majority of the Group’s businesses. Despite the ongoing
economic uncertainty in Europe, and the temporary impact of our
businesses that are in restructuring, organic growth remains above
our objective. We therefore remain confident that we should be able
to achieve our objectives for the full year 2013.”
9M 2013 EURm
9M 2013 9M 2012
% Growth
Eurofins Group Revenues
882.2 751.1 17.5%
Eurofins (Paris:ERF) generated revenues of EUR 882.2m during the
first nine months of the year, representing growth of 17.5%.
Organic growth was over 6%, currency translation had a negative
impact of 1.6%, and the remainder came from acquisitions. Adjusted
for businesses in significant restructuring, organic growth was
7.5%.
The Group’s continued strong performance reflects both the
attractive fundamentals of its businesses, and the benefits of its
leading position in most of the markets it serves. Robust growth in
food testing is driven by the increasing focus on risk management
across the food supply chain, regulation, and Eurofins’ entry into
new markets. Pharmaceutical testing delivered solid growth driven
by continued strength in pharmaceutical products testing and
genomics, offsetting the temporary impact of reorganization in the
Group’s central laboratory and discovery pharmacology businesses.
Environmental testing continues to be impacted by the IPL
restructuring in France, and overall slower environmental testing
activities in Europe.
The US and Germany (23% and 17% of Group revenues respectively),
both delivered strong organic growth of 10% in the first nine
months, driven by market growth and expansion in Eurofins’ market
share. In France, the impact of the ongoing IPL reorganization was
offset by the continued strong performance in food testing. The
double-digit organic growth in the UK (5% of revenues) came on the
back of an outsourcing contract, and to a lesser extent, the
horsemeat scandal. The Nordic countries have had stronger growth in
Q2 and Q3 following the weather-related slower start to the year.
Finally, strong growth in emerging markets and Asia Pacific
continues to expand these regions’ share of Group revenues.
For more information, please visit
www.eurofins.com
Notes for the editor:Eurofins – a global leader in
bio-analysisEurofins Scientific is the world leader in food and
pharmaceutical products testing. It is also number one in the world
in the field of environmental laboratory services and one of the
global market leaders in agroscience, genomics, discovery
pharmacology and central laboratory services.
With over 14,500 staff in more than 190 laboratories across 37
countries, Eurofins offers a portfolio of over 100,000 reliable
analytical methods for evaluating the safety, identity,
composition, authenticity, origin and purity of biological
substances and products. The Group provides its customers with
high-quality services, accurate results in time and expert advice
by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by
expanding both its technology portfolio and its geographic reach.
Through R&D and acquisitions, the Group draws on the latest
developments in the field of biotechnology and analytical chemistry
to offer its clients unique analytical solutions and the most
comprehensive range of testing methods.
As one of the most innovative and quality oriented international
players in its industry, Eurofins is ideally positioned to support
its clients’ increasingly stringent quality and safety standards
and the expanding demands of regulatory authorities around the
world.
The shares of Eurofins Scientific are listed on the NYSE
Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA,
Bloomberg ERF FP).
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgement
of Eurofins Scientific’ management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the data
available to the Company as of the date of publication, but no
guarantee can be made as to their validity.
Eurofins Investor RelationsPhone: +32-2-766 1620E-mail:
ir@eurofins.com
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Enerplus (NYSE:ERF)
Historical Stock Chart
From Jul 2023 to Jul 2024